Swog Cancer Research Network
Clinical trials sponsored by Swog Cancer Research Network, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Money help for cancer patients: study tests financial navigation Results expected Sep 2026 (estimated)
- New study aims to predict immunotherapy side effects Results expected Sep 2026 (estimated)
- New drug targets rare lung cancer mutation in advanced disease Results expected Dec 2026 (estimated)
- Expert panel boosts precision cancer care in new study Results expected Dec 2026 (estimated)
- New targeted therapy shows promise for Hard-to-Treat lung cancer Results expected Dec 2026 (estimated)
-
Head-to-Head: which JAK inhibitor wins for myelofibrosis patients with low blood counts?
Disease control Not yet recruitingThis study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…
Phase 4 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can adding capivasertib slow metastatic breast cancer?
Disease control Not yet recruitingThis trial tests whether adding the investigational drug capivasertib to standard hormone-blocking therapy and a CDK4/6 inhibitor can improve treatment response in people with HR-positive, HER2-negative metastatic breast cancer. Participants receive either the standard treatment …
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough lymphoma: Three-Drug showdown begins
Disease control Not yet recruitingThis phase II trial tests whether a drug called mosunetuzumab works better alone or combined with either zanubrutinib or polatuzumab vedotin for people with marginal zone lymphoma that has returned or stopped responding to treatment. The study will enroll 138 participants and mea…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for richter transformation: targeted drug combo heads to phase III
Disease control Not yet recruitingThis study tests whether adding the targeted drug pirtobrutinib to standard chemotherapy (R-CHOP) works better than chemo alone for people with Richter transformation, a rare and aggressive lymphoma that develops from chronic lymphocytic leukemia. About 102 adults will be randoml…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New combo aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis study tests whether adding a new drug called revumenib to the usual treatment (blinatumomab plus chemotherapy) can better clear leftover leukemia cells in people with a specific genetic type of B-cell acute lymphoblastic leukemia (ALL) or mixed-lineage leukemia. About 90 adu…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could 5 days of radiation replace 25 for sarcoma patients?
Disease control Not yet recruitingThis study compares a short course of radiation therapy (5 days) to the standard longer course (25 days) for people with soft tissue sarcoma in the arms or legs that can be removed with surgery. The goal is to see if the shorter treatment is just as effective at preventing the ca…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New trial aims to boost survival in HER2+ breast cancer by adding surgery and radiation to drug therapy
Disease control Not yet recruitingThis phase III trial is for people with HER2-positive stage IV breast cancer that has spread to a limited number of spots (oligometastatic). It tests whether adding surgery and focused radiation to standard drug therapy helps them live longer or delays cancer growth compared to d…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to shrink Hard-to-Treat lung tumors
Disease control Not yet recruitingThis study tests two drugs, sacituzumab govitecan and ivonescimab, alone or together, in people with advanced non-small cell lung cancer that has specific gene changes. The goal is to see if the combination works better than either drug alone at shrinking tumors and delaying canc…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC